| 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 份數目 | | | (請參閱上述*註解)有投票權股 (日 / 月 / 年) | | | | | | | | | 份百分比 | | | CS20251118E00015 | 兴证全球基金管理有限公司 | 1201(L) | | 935,900(L | HKD 41.5596 | 6.739.600(L) | 5.47(L)17/11/2025 | 泰格医药(3347.HK)今日盘中一度跌3.57%至39.44港元，股价创7月9日以来逾4个月新低。该股自上周五(11月14日)迄今已连续4个交易日下跌，累跌12.94%。 消息面上，联交所最新权益披露资料显示，泰格医药于11月17日遭兴证全球基金管理有限公司在场内以每股均价41.5596港元减持93.59万股，涉资约3889.56 万港元。减持后，其最新持股数目为673.96万股， ...

Core Viewpoint - Tiger Med's stock price has experienced a decline of 3.17% year-to-date, with a significant drop of 21.49% over the past 60 days, indicating potential challenges in the market [1] Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [1] - The main business segments include I to IV phase clinical trial technical services, data management and statistical analysis, registration application, clinical trial site services, SMO services, medical testing services, medical documentation translation, medical imaging diagnosis services, and training services [1] - The revenue composition is as follows: clinical trial-related services and laboratory services account for 52.60%, clinical trial technical services for 45.21%, and other services for 2.19% [1] Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2] - The top circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 25.097 million shares, and China Europe Medical Health Mixed A, which increased its holdings by 1.218 million shares [3]

Summary of Key Points Core Viewpoint - On November 17, 2025, CICC Global Fund Management Co., Ltd. reduced its stake in Tigermed (03347.HK) by selling 935,900 shares at an average price of HKD 41.5596 per share, totaling approximately HKD 38.8956 million. Following this transaction, CICC's holdings decreased from 6.23% to 5.47% of the total shares outstanding [1]. Group 1 - CICC Global Fund Management Co., Ltd. sold 935,900 shares of Tigermed at an average price of HKD 41.5596 per share [1]. - The total value of the shares sold by CICC was approximately HKD 38.8956 million [1]. - After the sale, CICC's total holdings in Tigermed were reduced to 6.7396 million shares, representing 5.47% of the total shares outstanding [1].

智通财经APP讯，泰格医药(03347)公布，公司于2025年11月18日收到持股5%以上股东、董事及总经理 曹晓春女士出具的《关于股份减持计划实施完成的告知函》。截至2025年11月18日，曹晓春女士本次股 份减持计划期限已届满，在减持计划期间，其合计减持34.76万股，占当前剔除回购专户股份数后公司 总股本的0.0406%，占公司A股总股本的0.0475%。 ...

泰格医药（300347）(03347)公布，公司于2025年11月18日收到持股5%以上股东、董事及总经理曹晓春 女士出具的《关于股份减持计划实施完成的告知函》。截至2025年11月18日，曹晓春女士本次股份减持 计划期限已届满，在减持计划期间，其合计减持34.76万股，占当前剔除回购专户股份数后公司总股本 的0.0406%，占公司A股总股本的0.0475%。 ...

HANGZHOU TIGERMED CONSULTING CO., LTD. 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：3347） 海外監管公告 本 公 告 乃 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）根 據 香 港 聯 合 交 易 所有限公司證券上市規則第13.10B條 而 作 出。 茲 載 列 本 公 司 於 深 圳 證 券 交 易 所 網 站 刊 登 公 告 如 下，僅 供 參 閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 杭州泰格醫藥科技股份有限公司 董事長 葉小平 香 港，2025年11月18日 於 本 公 告 日 期，執 行 董 事 為 葉 小 平 博 士、曹 曉 春 女 士、吳 灝 先 生 及 聞 增 玉 先 生；獨 立 非 執 行 董 ...

（编辑 任世碧） 证券日报网讯 11月18日晚间，泰格医药发布公告称，截至2025年11月18日，公司持股5%以上股东、董 事及总经理曹晓春女士本次股份减持计划期限已届满，在减持计划期间，其合计减持347，600股，占当 前剔除回购专户股份数后公司总股本的0.0406%，占公司A股总股本的0.0475%。 ...

Core Insights - The Medical Health R Index (480016) closed at 7508.88 points, down 0.45%, with a trading volume of 17.774 billion yuan and a turnover rate of 0.67% [1] - Among the index constituents, 16 stocks rose while 33 fell, with Bai Li Tian Heng leading the gainers at 2.32% and Tigermed leading the decliners at 3.42% [1] Index Performance - The top ten constituents of the Medical Health R Index include: - WuXi AppTec (sh603259) with a weight of 13.66%, latest price at 92.32, down 1.54%, and a market cap of 275.46 billion yuan - Hengrui Medicine (sh600276) with a weight of 11.00%, latest price at 61.78, down 0.03%, and a market cap of 410.05 billion yuan - Mindray Medical (sz300760) with a weight of 7.57%, latest price at 206.71, up 0.33%, and a market cap of 250.62 billion yuan - United Imaging Healthcare (sh688271) with a weight of 4.27%, latest price at 134.25, up 0.19%, and a market cap of 110.64 billion yuan - Other notable constituents include Pianzi Shou (sh600436), Yuan Er Fu Ke (sz300015), Kelun Pharmaceutical (sz002422), Xinhecheng (sz002001), Fosun Pharma (sh600196), and Ziji Shenzhou (sh688235) [1] Capital Flow - The Medical Health R Index constituents experienced a net outflow of 2.083 billion yuan from institutional investors, while retail investors saw a net inflow of 1.545 billion yuan [1] - Detailed capital flow for specific stocks shows: - Kelun Pharmaceutical (sz002422) had a net inflow of 23.33 million yuan from institutional investors but a net outflow from retail investors - Tongce Medical (600763) and Yirui Technology (688301) also showed mixed capital flows with varying net inflows and outflows [2]

MACD金叉信号形成，这些股涨势不错！ 格隆汇11月18日丨泰格医药(300347.SZ)公布，公司于2025年11月18日收到董事及总经理曹晓春女士出 具的《关于股份减持计划实施完成的告知函》。截至2025年11月18日，曹晓春女士本次股份减持计划期 限已届满，在减持计划期间，其合计减持34.76万股，占当前剔除回购专户股份数后公司总股本的 0.0406%，占公司A股总股本的0.0475%。 ...

Core Viewpoint - The major shareholder of Tiger Med, Ms. Cao Xiaochun, has completed her share reduction plan, selling a total of 347,600 shares, which represents 0.0406% of the company's total share capital after excluding repurchased shares [1] Summary by Sections - Shareholder Activity - Ms. Cao Xiaochun reduced her holdings by 347,600 shares during the designated reduction period [1] - Following the reduction, she holds 51,314,174 shares, accounting for 6.0007% of the total share capital [1] - Impact on Company Structure - The share reduction did not result in any change in the company's control [1] - The governance structure and ongoing operations of the company remain unaffected [1]